(3-ethylphenyl)methanol | 53957-34-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-ethylphenyl)methanol
• CAS: 53957-34-9
• 化学式: C₉H₁₂O
• 分子量: 136.194
• InChiKey: JBXKSUUBAYVELX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3-ethylphenyl)methanol 在 四(三苯基膦)钯 、 正丁基锂 、 三溴化磷 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 、 正己烷 为溶剂， 反应 43.66h， 生成 [(1S)-1-chloro-2-(3-ethylphenyl)ethyl]boronic acid (+)-pinane-2,3-diyl diester
  参考文献：
  名称：

  [EN] BORONIC ACID DERIVATIVES
  [FR] DÉRIVÉS D'ACIDE BORONIQUE

  摘要：

  式（I）的化合物是LMP7的抑制剂，可用于治疗自身免疫性疾病或血液系统恶性肿瘤，等等。

  公开号：

  WO2016050355A1
• 作为产物：
  描述：

  3-乙基甲苯 在 Cellulosimicrobium cellulans EB-8-4 作用下， 反应 10.0h， 以52%的产率得到(3-ethylphenyl)methanol
  参考文献：
  名称：

  Highly chemo- and regio-selective hydroxylations of o- and m-substituted toluenes to benzyl alcohols with Cellulosimicrobium cellulans EB-8-4

  摘要：

  Highly chemo- and regio-selective benzylic hydroxylations of o- and m-substituted toluenes were achieved with the easily available and easy-to-handle resting cells of Cellulosimicrobium cellulans EB-8-4 as biocatalysts, giving the corresponding benzyl alcohols as single product. Benzyl alcohols were obtained in 78-94% yield, demonstrating the first green, clean, and simple method for the preparation of benzyl alcohols via hydroxylations. Biotransformation of 4-methylbenzyl chloride with the same strain gave 4-methylbenzyl alcohol in 67-81% yield, suggesting a novel dehalogenation activity of the cells and providing a novel, green, and efficient method for the preparation of 4-methylbenzyl alcohol as well as the application potential in biodegradation of chlorine-containing aromatics. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.06.039

文献信息

• Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity
  申请人：——

  公开号：US20020120011A1

  公开（公告）日：2002-08-29

  The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted diamines. A preferred specific N,N-disubstituted diamine is the compound: 1

  这项发明涉及替代多环芳基和杂环芳基的三级杂烷基胺化合物，可用作胆固醇酯转移蛋白（CETP；血浆脂质转移蛋白-I）的抑制剂，以及用于治疗动脉粥样硬化和其他冠状动脉疾病的化合物、组合物和方法。首选的三级杂烷基胺化合物是取代的N,N-二取代二胺。首选的具体N,N-二取代二胺化合物是：1
• Chemoselective Hydrogenation and Transfer Hydrogenation of Olefins and Carbonyls with the Cluster-Derived Ruthenium Nanocatalyst in Water
  作者：Arindam Indra、Prasenjit Maity、Sumit Bhaduri、Goutam Kumar Lahiri

  DOI：10.1002/cctc.201200448

  日期：2013.1

  ammonium groups of water‐soluble poly(diallyldimethylammonium chloride) gives the precursor of a nanocatalyst for hydrogenation and transfer hydrogenation reactions in water. In hydrogenation reactions, “on water” effect is seen for substrates such as cyclohexanones, methyl pyruvate, acetophenone, and safflower oil. With these substrates, higher turnover numbers are obtained in water than in methanol

  [H 3 Ru 4（CO）12 ] -与水溶性聚（二烯丙基二甲基氯化铵）的季铵根离子配对为纳米催化剂的前体，用于水中的氢化和转移氢化反应。在氢化反应中，对于环己酮，丙酮酸甲酯，苯乙酮和红花油等底物，可以看到“水上”效应。使用这些底物，在水中比在甲醇中获得更高的周转率。团簇衍生的催化剂表现出独特的化学选择性，这在通过[RuCl 4 ] -与同一聚合物的季铵基团离子配对制备的催化剂中，或者在市售（5％）Ru / Al中都看不到。2 O 3。与此相反的Ru / Al的2 Ó 3中，将[RuCl 4 ] -衍生的催化剂，或许多其它基于钌的催化系统中，簇衍生的催化剂是完全惰性的朝向的氢化 NO 2，CN和芳环官能团。在水中，通过使用簇状催化剂和甲酸盐作为氢供体，可以减少典型的酮和醛。因此，可以由相应的醛制得工业上重要的氰基和硝基苄基醇。高分辨率TEM数据表明，独特的化学选择性是高度结晶的钌纳米颗粒的结果，该纳米颗粒主要由Ru（1
• 2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent
  申请人：Astra Pharmaceuticals Limited

  公开号：US06107297A1

  公开（公告）日：2000-08-22

  The invention relates to new pharmaceutically active compounds which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.

  本发明涉及新的药物活性化合物，这些化合物是P2-嘌呤受体7-跨膜(TM)G-蛋白偶联受体拮抗剂，包含它们的组合物以及它们的制备方法。
• PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：dos Santos Jean Leandro

  公开号：US20120115817A1

  公开（公告）日：2012-05-10

  The present invention relates to phthalimide derivatives of non-steroidal and/or TNF-α modulating anti-inflammatory compounds as well as the process of obtaining the so-called derivatives, pharmaceutical compositions containing such derivatives and their uses, including use in the treatment of inflammatory diseases, especially those related to chronic inflammatory processes, such as rheumatoid arthritis and intestinal inflammatory diseases (for instance, Chron's disease) and the use of the referred to pharmaceutical compositions as antipyretic, analgesic and platelet antiaggregating medications.

  本发明涉及非甾体和/或调节肿瘤坏死因子-α（TNF-α）的抗炎化合物的酞酰亚胺衍生物，以及获得所述衍生物的方法、包含该衍生物的药物组合物及其用途，包括用于治疗炎症疾病，尤其是与慢性炎症过程相关的疾病，例如类风湿性关节炎和肠道炎症疾病（例如，克罗恩病），以及将所述药物组合物用作退热剂、镇痛剂和抗血小板聚集药物的使用。
• Anti-infective agents
  申请人：Technische Universität Carolo-Wilhelmina zu Braunschweig

  公开号：EP1972338A1

  公开（公告）日：2008-09-24

  The present invention relates to the use of molecules having a spacer unit, linker and recognition unit(s) for the treatment and prevention of various diseases, disorders and conditions. In particular, the present invention provides compounds useful in preventing or treating infectious diseases and diseases, disorders or conditions related thereto. Further, the present invention relates to methods for preventing or treating diseases, disorders or conditions involving recognition and binding of carbohydrate structures.

  本发明涉及具有间隔单元、连接单元和识别单元的分子的使用，用于治疗和预防各种疾病、紊乱和病况。具体而言，本发明提供了在预防或治疗传染病和与之相关的疾病、紊乱或病况中有用的化合物。此外，本发明涉及预防或治疗涉及糖类结构的识别和结合的疾病、紊乱或病况的方法。